Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Common Equity (2016 - 2025)

Palisade Bio (PALI) has disclosed Common Equity for 16 consecutive years, with $3.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity fell 51.39% to $3.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.2 million, a 51.39% decrease, with the full-year FY2024 number at $7.5 million, down 33.78% from a year prior.
  • Common Equity was $3.2 million for Q3 2025 at Palisade Bio, up from $2.6 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $15.8 million in Q2 2023 to a low of -$20.1 million in Q1 2021.
  • A 5-year average of $6.0 million and a median of $7.0 million in 2024 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: tumbled 96.14% in 2021, then skyrocketed 275.21% in 2023.
  • Palisade Bio's Common Equity stood at $3.9 million in 2021, then skyrocketed by 218.34% to $12.5 million in 2022, then decreased by 9.34% to $11.3 million in 2023, then crashed by 33.78% to $7.5 million in 2024, then plummeted by 57.13% to $3.2 million in 2025.
  • Per Business Quant, the three most recent readings for PALI's Common Equity are $3.2 million (Q3 2025), $2.6 million (Q2 2025), and $5.3 million (Q1 2025).